ACADIA Pharmaceuticals, Inc. (NASDAQ:ACAD)

CAPS Rating: 2 out of 5

The Company is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders.

Recs

0
Player Avatar TMFBiologyFool (95.87) Submitted: 11/27/2012 4:18:10 PM : Underperform Start Price: $4.92 ACAD Score: -343.79

No catalyst for awhile. And second phase 3 isn't a sure thing. Placebo effect is hard to beat twice.

Featured Broker Partners


Advertisement